drugset
drugset / Trial / NCT04666922

A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080

NCT04666922 ↗

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 765080 in healthy male subjects following intravenous administration of single rising doses.

Timeline

Start
2021-01-14
Primary completion
2021-08-25
Completion
2021-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 765080 Unknown 1 mg Intravenous
Subject BI 765080 Unknown 10 mg Intravenous
Subject BI 765080 Unknown 25 mg Intravenous
Subject BI 765080 Unknown 50 mg Intravenous
Subject BI 765080 Unknown 100 mg Intravenous
Subject BI 765080 Unknown 200 mg Intravenous

Indications

No indication recorded.